The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Deciphering the tumor microenvironment (TME) dynamics in advanced colorectal (CRC) and pancreatic cancers (PDAC) treated with durvalumab (D) with olaparib (O) or cediranib (C): Results from a phase 2 randomized trial.
 
Alberto Hernando-Calvo
Travel, Accommodations, Expenses - Kyowa Kirin International; Merck Serono
 
Ming Han
No Relationships to Disclose
 
Olubukola Ayodele
No Relationships to Disclose
 
Ben X Wang
Honoraria - AstraZeneca; Tessa Therapeutics
Consulting or Advisory Role - Providence Therapeutics
 
Maria Vila-Casadesús
No Relationships to Disclose
 
S Y Cindy Yang
No Relationships to Disclose
 
Hal Berman
No Relationships to Disclose
 
Ana Vivancos
Stock and Other Ownership Interests - Reveal Genomics
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Guardant Health; Incyte; Merck; Roche
Research Funding - Bristol Meyers Squibb (Inst); Incyte (Inst); Roche (Inst)
 
Bernard Lam
No Relationships to Disclose
 
Ilinca Lungu
No Relationships to Disclose
 
Abdulazeez Salawu
No Relationships to Disclose
 
Lee-Anne Stayner
No Relationships to Disclose
 
Benjamin Haibe-Kains
Stock and Other Ownership Interests - Code Biotherapeutics; IONIQ Sciences
Honoraria - Takeda
Consulting or Advisory Role - Break Through Cancer; CQDM
Travel, Accommodations, Expenses - Roche; Takeda
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Gilead Sciences; Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
 
Lisa Avery
No Relationships to Disclose
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; GlaxoSmithKline; Inhibrx; Medison
Research Funding - 23 and Me; Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; Frontier Therapeutics; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison
 
Trevor John Pugh
Honoraria - AstraZeneca; Illumina; Merck; PACT Pharma
Consulting or Advisory Role - Axiom Healthcare Strategies; Chrysalis Biomedical Advisors; SAGA Diagnostics
Research Funding - Roche
Patents, Royalties, Other Intellectual Property - Hybrid-capture sequencing for dete rmining immune cell clonality
 
Anna Spreafico
Honoraria - Immunocore; Medison
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Medison; Merck
Research Funding - Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Nubiyota (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Surface Oncology (Inst); Symphogen (Inst); Treadwell Therapeutics (Inst)
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)